IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure

Background: Increased activity of IGFBP7 (insulin-like growth factor–binding protein-7) is associated with cellular senescence, tissue aging, and obesity. IGFBP7 may be related to heart failure with preserved ejection fraction, a disease of elderly obese people. Methods and Results: In a subset of patients with heart failure with preserved ejection fraction (N=228) randomized to receive sacubitril/valsartan versus valsartan, IGFBP7 concentrations were measured at baseline, 12 weeks, and 36 weeks. Patient characteristics and echocardiographic measures including left atrial (LA) size and volume, ratio of early mitral inflow velocity/annular diastolic velocity, and ratio of early diastole/peak late diastolic velocity were assessed as a function of IGFBP7 concentration. Effect of sacubitril/valsartan on IGFBP7 concentrations was analyzed. With increasing baseline IGFBP7 quartiles, LA size and LA volume index (LAVi) were higher (both P<0.001); modest association between IGFBP7 and higher early mitral inflow velocity/annular diastolic velocity (P=0.03) and early diastole/peak late diastolic velocity ratio (P=0.04) was also seen. IGFBP7 concentrations were higher in those with LAVi ≥34 mL/m2 compared with lower LAVi at all time points (all P<0.01). IGFBP7 independently predicted LAVi at baseline even in the presence of NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentrations; highest LAVi was seen in those with elevation in both biomarkers. Treatment with sacubitril/valsartan resulted in lower IGFBP7 concentrations over 36 weeks compared with valsartan (adjusted treatment effect, −7%; P<0.001). Conclusions: Among patients with heart failure with preserved ejection fraction, concentrations of the cellular senescence biomarker IGFBP7 were associated with abnormalities in diastolic filling and LA dilation. Treatment with sacubitril/valsartan resulted in lower IGFBP7 concentrations compared with valsartan. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00887588.

[1]  Y. Goshima,et al.  Reduction and fragmentation of elastic fibers in the skin of obese mice is associated with altered mRNA expression levels of fibrillin-1 and neprilysin , 2017, Connective tissue research.

[2]  Biao Xu,et al.  Premature senescence of cardiac fibroblasts and atrial fibrosis in patients with atrial fibrillation , 2017, Oncotarget.

[3]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.

[4]  C. Vrints,et al.  Endothelial Senescence Contributes to Heart Failure With Preserved Ejection Fraction in an Aging Mouse Model , 2017, Circulation. Heart failure.

[5]  R. Kim,et al.  Redefining the role of biomarkers in heart failure trials: expert consensus document , 2017, Heart Failure Reviews.

[6]  Y. Koh,et al.  Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway , 2017, Molecular and Cellular Biochemistry.

[7]  R. McKelvie,et al.  Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. , 2017, Journal of cardiac failure.

[8]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.

[9]  K. Anstrom,et al.  Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. , 2016, JACC. Heart failure.

[10]  M. Konstam,et al.  Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials , 2016, Circulation. Heart failure.

[11]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[12]  S. Solomon,et al.  Left Atrial Structure and Function Across the Spectrum of Cardiovascular Risk in the Elderly: The Atherosclerosis Risk in Communities Study , 2016, Circulation. Cardiovascular imaging.

[13]  J. Kellum,et al.  Cell-cycle arrest and acute kidney injury: the light and the dark sides , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  S. Solomon,et al.  Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection FractionCLINICAL PERSPECTIVE , 2016 .

[15]  S. Solomon,et al.  Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. , 2016, Circulation. Heart failure.

[16]  A. Sheftel,et al.  Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? , 2014, The American journal of cardiology.

[17]  S. Solomon,et al.  Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696 , 2014, Circulation. Heart failure.

[18]  Richard T. Lee,et al.  Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. , 2014, Circulation research.

[19]  Milton Packer,et al.  Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[20]  A. Chambery,et al.  Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells , 2013, Cell Death and Disease.

[21]  A. Gramolini,et al.  Pilot study identifying myosin heavy chain 7, desmin, insulin‐like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure , 2013, Proteomics.

[22]  E. Hara,et al.  Roles and mechanisms of cellular senescence in regulation of tissue homeostasis , 2013, Cancer science.

[23]  Azra Bihorac,et al.  Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury , 2013, Critical Care.

[24]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[25]  M. Maurer,et al.  Heart failure with a preserved ejection fraction: what is in a name? , 2011, Journal of the American College of Cardiology.

[26]  A. Balmforth,et al.  Neprilysin, obesity and the metabolic syndrome , 2010, International Journal of Obesity.

[27]  Y. Takema,et al.  Neprilysin Is Identical to Skin Fibroblast Elastase , 2010, The Journal of Biological Chemistry.

[28]  D. Kass,et al.  Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. , 2007, Journal of the American College of Cardiology.

[29]  J. Fernández-Real,et al.  Insulin Resistance Is Associated With Increased Serum Concentration of IGF-Binding Protein–Related Protein 1 (IGFBP-rP1/MAC25) , 2006, Diabetes.

[30]  J. Cuzick,et al.  A Wilcoxon-type test for trend. , 1985, Statistics in medicine.